Aurinia Pharmaceuticals (AUPH) PT Lowered to $6 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
- Wall Street set to open lower as high-stakes Iran, inflation tests loom
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
May 2, 2024 6:00 AM EDTAchieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in LUPKYNIS® (voclosporin) sales Rapidly completed restructuring while maintaining focus on commercial execution Ahead of prior projections, Company expects to be cash flow positive, excluding share repurchases, in second quarter 2024, with estimated cost savings of $50 to $55 million annually Company reiterates 2024 net product revenue guidance of $200 to $220 million
Conference call to be hosted today at 8:30 a.m.... More
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
May 1, 2024 6:00 AM EDTROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.
Aurinia is on a mission to tackle the toughest challenges that the LN community faces through collaborative efforts with key stakeholders across the healthcare ecosystem, including patients, healthcare professionals (HCPs), and policymakers. Through awareness, education, advocacy, and... More
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
April 30, 2024 6:00 AM EDTNew data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year of treatment Safety profile remains unchanged and is aligned with the safety findings in the AURORA clinical program
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the FDA has approved a label update for LUPKYNIS. The updated label no longer includes language indicating that the safety and efficacy of... More
